March 7th 2025
The novel nitric oxide-donating bimatoprost eye drop is designed to lower IOP in patients with open-angle glaucoma or ocular hypertension
February 10th 2025
December 23rd 2024
Navigating the Advances in the Treatment of Geographic Atrophy: Updates and Strategies for Managed Care
View More
CRU Eye Symposium
March 28-30, 2025
Register Now!
Eye Care Symposia in Los Angeles
April 25-26, 2025
Register Now!
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (CME Track)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (CME Track)
View More
Assessing the Evidence for Extending Treatment Intervals in nAMD and DME Management – Expert Insights into Innovative Approaches (COPE Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (CME Track)
View More
Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics (COPE Track)
View More
Surv.AI Says: Real-World Insights Into Patient Burden & Evolving Strategies in nAMD and DME (CME Credit)
View More
Surv.AI Says: Real-World Insights into Patient Burden & Evolving Strategies in nAMD and DME (COPE Credit)
View More
Community Practice Connections™: Mastering the New Treatment Paradigm in Geographic Atrophy – From Detection to Intervention (COPE Track)
View More
Community Practice Connections™: Optimizing Outcomes in Glaucoma Management - Applying Evidence to Practice with a Multitude of Treatment Options (COPE Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (CME Track)
View More
Reimagining Dry Eye Disease: Delineating the Role of Evaporation From Inflammation and Insights Into Optimizing Treatment (COPE Track)
View More
19th Annual Controversies in Modern Eye Care
May 4, 2025
Register Now!
(CME Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
(COPE Track) Community Practice Connections™: Advancing the Optimal Diagnosis & Treatment of Thyroid Eye Disease
View More
(CME) Community Practice Connections™: A Closer Look at Neurotrophic Keratitis—Ensuring Timely Diagnosis and Taking Early Action
View More
Outlining the New Standard in Geographic Atrophy: Optimizing Care Within the Modern Treatment Paradigm (CME Track)
View More
Outlining the New Standard in Geographic Atrophy: Optimizing Care Within the Modern Treatment Paradigm (COPE Track)
View More
Collaborative Care Symposium
May 30-31, 2025
Register Now!
Community Practice Connections™: Novel Therapies for Neovascular Retinal Disease – Expert Analysis of New Key Data
View More
Latest Advances in X-Linked Retinitis Pigmentosa: Optimizing Diagnosis and Developments in Gene Therapy
View More
Cases & Conversations™: Real World Review of Treat and Extend Strategies for Neovascular Retinal Disease
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (CME Track)
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (COPE Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (CME Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (COPE Track)
View More
Burst CME Plus™ - Unveiling Pharmacological Advances in nAMD & DME: From Durability to Applicability
View More
Are patients with diabetes more susceptible to open angle glaucoma?
April 1st 2009Dr Vikas Shankar has found that in the diabetic population with OAG, the optic nerve damage occurs at a lower intraocular pressure in comparison with the non-diabetic OAG population and asks: does screening hold the key?
BAK-free latanoprost: safe and effective
March 11th 2009The first data on Nova21027 (Novagali Pharma), a benzalkonimum chloride (BAK)-free latanoprost cationic emulsion, have been announced at the Scientific Meeting of the Association for Ocular Pharmacology and Therapeutics (AOPT) in Salzburg, Austria.
Motion Displacement Test on show for World Glaucoma Day
March 11th 2009The Motion Displacement Test (MDT), developed by Moorfields Eye Hospital in partnership with UCL Institute of Ophthalmology and City University London will be on show during World Glaucoma Day (March 12th) to demonstrate some of the latest glaucoma diagnostic equipment.